We now have two randomised phase III trials showing level one evidence that PARP inhibitors for patients with metastatic breast cancer who have a germline BRCA mutation and HER2 negative breast cancer show benefit, improving median progression free survival as well as quality of life measures compared to standard chemotherapy.

So this is a standard of care option for patients now who fit those criteria but we’re still not curing patients with the PARP inhibitors across the board; we’re seeing resistance. We need to see if we can expand the patients who might benefit from PARP inhibitors, so patients who maybe don’t have a germline BRCA but maybe have other mutations, either in their germline or that we find in the tumour. And a lot of research is trying to understand that group of patients who don’t have responses to PARP inhibitors, despite having a germline BRCA mutation. All of those investigations are ongoing.